<?xml version='1.0' encoding='utf-8'?>
<section xmlns:codified="https://code.dccouncil.us/schemas/codified" xmlns:codify="https://code.dccouncil.us/schemas/codify" xmlns:xi="http://www.w3.org/2001/XInclude" containing-doc="D.C. Code">
  <num>48-842.02</num>
  <heading>Definitions.</heading>
  <text>For the purposes of this chapter, the term:</text>
  <para>
    <num>(1)</num>
    <text>“Medication advisory committee” means any committee or panel that is responsible for making recommendations or decisions regarding a formulary to be used by a health program administered by the government of the District of Columbia.</text>
  </para>
  <para>
    <num>(2)</num>
    <text>“Pharmaceutical company” means any entity that is engaged in, either directly or indirectly, the production, preparation, propagation, compounding, manufacturing, conversion or processing of a drug or biological product, including any person acting as its agent or representative.</text>
  </para>
  <annotations>
    <annotation doc="D.C. Law 17-131" type="History">Mar. 26, 2008, D.C. Law 17-131, § 302, 55 DCR 1659</annotation>
  </annotations>
</section>
